deferoxamine has been researched along with Diabetes Mellitus in 35 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 7.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 3.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "Diabetes mellitus was present in 6." | 2.61 | Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis. ( Chen, DY; Chen, W; He, LN; Liu, NQ; Lu, D; Sun, XF; Xie, YJ; Xiong, ZY; Yang, Y; Yang, YH, 2019) |
| " This substance is well absorbed orally and has been shown to enhance the excretion of ferric ion in iron loaded rats." | 2.36 | [Iron chelation. Biological significance and medical application]. ( Peter, HH, 1983) |
| "A hallmark of diabetes mellitus is the breakdown of almost every reparative process in the human body, leading to critical impairments of wound healing." | 1.46 | Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. ( Dong, Y; Duscher, D; Gurtner, GC; Hu, MS; Januszyk, M; Khong, SM; Longaker, MT; Maan, ZN; Walmsley, GG; Whittam, AJ, 2017) |
| "Diabetes mellitus was diagnosed in two patients, and impaired glucose tolerance was found in four patients, giving a prevalence of impaired glucose metabolism of 12." | 1.35 | Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. ( Chareonmuang, R; Jaruratanasirikul, S; Laosombat, V; Leetanaporn, K; Sangsupavanich, P; Wongcharnchailert, M, 2008) |
| "Idiopathic hemochromatosis is an iron-storage disease more common in men than in women." | 1.26 | Idiopathic hemochromatosis: case report of a patient presenting with neurologic symptoms. ( Afrooz, N; Sinclair, WP, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (42.86) | 18.7374 |
| 1990's | 4 (11.43) | 18.2507 |
| 2000's | 7 (20.00) | 29.6817 |
| 2010's | 5 (14.29) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ozkan, S | 1 |
| Isildar, B | 1 |
| Ercin, M | 1 |
| Gezginci-Oktayoglu, S | 1 |
| Konukoglu, D | 1 |
| Neşetoğlu, N | 1 |
| Oncul, M | 1 |
| Koyuturk, M | 1 |
| Deng, M | 1 |
| Wu, Y | 1 |
| Ren, Y | 1 |
| Song, H | 1 |
| Zheng, L | 1 |
| Lin, G | 1 |
| Wen, X | 1 |
| Tao, Y | 1 |
| Kong, Q | 1 |
| Wang, Y | 1 |
| Feng, Y | 1 |
| Jia, L | 1 |
| Ma, W | 1 |
| Tian, C | 1 |
| Du, H | 1 |
| Ding, Z | 1 |
| Zhang, Y | 2 |
| Guo, P | 1 |
| Duan, T | 1 |
| Cheng, W | 1 |
| Guo, Y | 1 |
| Zheng, X | 1 |
| Lu, G | 1 |
| Lu, Q | 1 |
| Kaplan, DL | 1 |
| He, LN | 1 |
| Chen, W | 1 |
| Yang, Y | 1 |
| Xie, YJ | 1 |
| Xiong, ZY | 1 |
| Chen, DY | 1 |
| Lu, D | 1 |
| Liu, NQ | 1 |
| Yang, YH | 1 |
| Sun, XF | 1 |
| Wong, CM | 1 |
| Huang, Y | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Duscher, D | 1 |
| Januszyk, M | 3 |
| Maan, ZN | 1 |
| Whittam, AJ | 1 |
| Hu, MS | 1 |
| Walmsley, GG | 1 |
| Dong, Y | 1 |
| Khong, SM | 1 |
| Longaker, MT | 1 |
| Gurtner, GC | 3 |
| Thangarajah, H | 2 |
| Yao, D | 2 |
| Chang, EI | 2 |
| Shi, Y | 2 |
| Jazayeri, L | 1 |
| Vial, IN | 2 |
| Galiano, RD | 2 |
| Du, XL | 1 |
| Grogan, R | 1 |
| Galvez, MG | 2 |
| Brownlee, M | 2 |
| Grogan, RH | 1 |
| Glotzbach, JP | 1 |
| Wong, VW | 1 |
| WOEHLER, F | 1 |
| VACHON, A | 1 |
| PALIARD, P | 1 |
| TETE, R | 1 |
| PESTEL, M | 1 |
| Tilbrook, L | 1 |
| Platis, O | 1 |
| Anagnostopoulos, G | 1 |
| Farmaki, K | 1 |
| Posantzis, M | 1 |
| Gotsis, E | 1 |
| Tolis, G | 1 |
| Wang, CH | 1 |
| Wu, KH | 1 |
| Tsai, FJ | 1 |
| Peng, CT | 1 |
| Tsai, CH | 1 |
| Jaruratanasirikul, S | 1 |
| Chareonmuang, R | 1 |
| Wongcharnchailert, M | 1 |
| Laosombat, V | 1 |
| Sangsupavanich, P | 1 |
| Leetanaporn, K | 1 |
| Fasano, A | 1 |
| Colosimo, C | 1 |
| Miyajima, H | 1 |
| Tonali, PA | 1 |
| Re, TJ | 1 |
| Bentivoglio, AR | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Bannerman, RM | 1 |
| Keusch, G | 1 |
| Kreimer-Birnbaum, M | 1 |
| Vance, VK | 1 |
| Vaughan, S | 1 |
| Peter, HH | 1 |
| al-Refaie, FN | 1 |
| Wonke, B | 2 |
| Wickens, DG | 1 |
| Aydinok, Y | 1 |
| Fielding, A | 1 |
| Hoffbrand, AV | 1 |
| Wong, V | 1 |
| Li, A | 1 |
| Lee, AC | 1 |
| Schleicher, ED | 1 |
| Wagner, E | 1 |
| Nerlich, AG | 1 |
| Calleja, EM | 1 |
| Shen, JY | 1 |
| Lesser, M | 1 |
| Grady, RW | 1 |
| New, MI | 1 |
| Giardina, PJ | 1 |
| Simon, M | 1 |
| Bourel, M | 1 |
| Sinclair, WP | 1 |
| Afrooz, N | 1 |
| De Sanctis, V | 1 |
| D'Ascola, G | 1 |
| Giorgio, AJ | 1 |
| de Haan, BB | 1 |
| Scherrer, JR | 1 |
| Stauffacher, W | 1 |
| Pometta, D | 1 |
| Ghidoni, A | 2 |
| Sanesi, E | 1 |
| Pozza, G | 2 |
| Darnis, F | 1 |
| Mossé, A | 1 |
| Breauté, C | 1 |
| Delorme, ML | 1 |
| Rosen, BJ | 1 |
| Tullis, JL | 1 |
| Lawecki, J | 1 |
| Rogala, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for deferoxamine and Diabetes Mellitus
| Article | Year |
|---|---|
Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis.
Topics: beta-Thalassemia; Chelation Therapy; Deferoxamine; Diabetes Mellitus; Endocrine System Diseases; Glu | 2019 |
[Iron chelation. Biological significance and medical application].
Topics: Animals; Bacterial Infections; Catechols; Deferoxamine; Diabetes Mellitus; Enterobactin; Female; Hum | 1983 |
[Idiopathic haemochromatosis. I. Clinical, biological and therapeutic aspects (author's transl)].
Topics: Bloodletting; Bone Diseases; Cardiomyopathies; Deferoxamine; Diabetes Mellitus; Female; Ferritins; H | 1979 |
2 trials available for deferoxamine and Diabetes Mellitus
| Article | Year |
|---|---|
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Thera | 2004 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
30 other studies available for deferoxamine and Diabetes Mellitus
| Article | Year |
|---|---|
Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic nephropathy model.
Topics: Animals; Creatinine; Culture Media, Conditioned; Deferoxamine; Diabetes Mellitus; Diabetic Nephropat | 2022 |
Clickable and smart drug delivery vehicles accelerate the healing of infected diabetic wounds.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Deferoxamine; Diabetes Mellitus; Humans; Hyaluronic | 2022 |
Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats.
Topics: Animals; Deferoxamine; Diabetes Mellitus; Diabetic Nephropathies; Fibrosis; Inflammation; Iron; Iron | 2023 |
Injectable Desferrioxamine-Laden Silk Nanofiber Hydrogels for Accelerating Diabetic Wound Healing.
Topics: Deferoxamine; Diabetes Mellitus; Endothelial Cells; Hydrogels; Nanofibers; Silk; Wound Healing | 2021 |
Bone morphogenic protein-4-induced oxidant signaling via protein carbonylation for endothelial dysfunction.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Apoptosis; Bone Morphogenetic Protein 4; Cel | 2014 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing.
Topics: Age Factors; Amino Acids, Dicarboxylic; Animals; Deferoxamine; Diabetes Mellitus; Hyperglycemia; Iro | 2017 |
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.
Topics: Animals; Cells, Cultured; Deferoxamine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus | 2009 |
HIF-1alpha dysfunction in diabetes.
Topics: Animals; Deferoxamine; Diabetes Mellitus; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit | 2010 |
THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE.
Topics: Anemia; Anemia, Macrocytic; Deferoxamine; Diabetes Mellitus; Ferritins; Hemochromatosis; Hemoglobins | 1963 |
[COURSE OF THE DIABETES OF HEMOCHROMATOSIS UNDER THE INFLUENCE OF BLOODLETTING AND THE BLOODLETTING-DESFERRIOXAMINE COMBINATION].
Topics: Bloodletting; Deferoxamine; Diabetes Mellitus; Hemochromatosis; Hydroxamic Acids | 1963 |
[HEMOCHROMATOSIS].
Topics: Alcoholism; Biopsy; Blood Chemical Analysis; Bloodletting; Chelating Agents; Deferoxamine; Diabetes | 1964 |
Cross talk between iron metabolism and diabetes.
Topics: Aged; Amino Acids; Arteriosclerosis; Chromium; Cytokines; Deferoxamine; Diabetes Mellitus; Diabetes | 2004 |
Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy.
Topics: Adolescent; Area Under Curve; beta-Thalassemia; Chelation Therapy; Child; Cross-Sectional Studies; D | 2008 |
Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability.
Topics: Brain; Ceruloplasmin; Deferoxamine; Diabetes Mellitus; Disease Progression; Family; Female; Heredode | 2008 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria.
Topics: Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus; Folic Acid; Folic Acid Deficiency; Heart | 1967 |
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
Topics: Adolescent; Adult; Blood Glucose; Deferiprone; Deferoxamine; Diabetes Mellitus; Female; Glucose Tole | 1994 |
Neurophysiologic study of beta-thalassemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Brain; Copper; Deferoxamine; Diabetes Mellitus; Electrooculogra | 1993 |
Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.
Topics: Adult; Aged; Aging; Antibodies; Arteries; Arteriosclerosis; Biomarkers; Blood Proteins; Catalase; Ch | 1997 |
Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Defero | 1998 |
Idiopathic hemochromatosis: case report of a patient presenting with neurologic symptoms.
Topics: Aged; Deferoxamine; Diabetes Mellitus; Female; Heart Failure; Hemochromatosis; Humans; Iron; Liver C | 1977 |
The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.
Topics: Adolescent; Adult; Blood Glucose; Child; Chronic Disease; Deferoxamine; Diabetes Mellitus; Female; F | 1986 |
Primary hemochromatosis: easily missed cause of cirrhosis, diabetes and heart failure.
Topics: Age Factors; Aged; Blood Cell Count; Bloodletting; Deferoxamine; Diabetes Mellitus; Female; Heart Fa | 1973 |
Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis.
Topics: Adolescent; Adult; Age Factors; Blood Glucose; Deferoxamine; Diabetes Mellitus; Female; Glucose Tole | 1973 |
Effect of desferrioxamine methansulphonate (DFOM) on glucose uptake by rat epididymal adipose tissue.
Topics: Adipose Tissue; Animals; Deferoxamine; Diabetes Mellitus; Edetic Acid; Glucose; Hemochromatosis; In | 1966 |
[Present aspects of the treatment of hemochromatosis (apropos of 100 observations)].
Topics: Adult; Alcoholic Intoxication; Bloodletting; Chelating Agents; Chondrocalcinosis; Deferoxamine; Diab | 1971 |
Studies on the diabetic syndrome of idiopathic haemochromatosis.
Topics: Adult; Aged; Blood Glucose; Deferoxamine; Diabetes Mellitus; Glucose Tolerance Test; Hemochromatosis | 1968 |
Simplified deferoxamine test in normal, diabetic, and iron-overload patients. Clinical observations.
Topics: Adult; Aged; Blood; Deferoxamine; Diabetes Mellitus; Female; Hemochromatosis; Hemoglobins; Humans; I | 1966 |
[A case of primary hemochromatosis treated with desferol].
Topics: Aged; Carbohydrate Metabolism; Deferoxamine; Diabetes Mellitus; Hemochromatosis; Humans; Iron; Male | 1966 |